This database contains 472 studies, archived under the term: "Pharmaceutical Interventions"
Click here to filter this large number of results.
Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008
Lazzeroni, Laura C.,
Halbauer, Joshua D.,
Ashford, J. Wesson,
Noda, Art,
Hernandez, Beatriz,
Azor, Virgina,
Hozack, Nikki,
Hasson, Noelle,
Henderson, Victor W.,
Yesavage, Jerome A.,
Tinklenberg, Jared R.
Alzheimer’s disease (AD) shortens life-expectancy, but the effects of pharmacological treatments for this disorder on mortality have not been studied. We compared two commonly prescribed medications, donepezil and memantine, with respect to the length of survival of veterans presumed to have AD. The Computerized Medical Records System at the Veterans Affairs Palo Alto Health Care […]
Risk of cerebrovascular accident associated with use of antipsychotics: population-based case-control study
Laredo, Leonor,
Vargas, Emilio,
Blasco, Antonio Javier,
Aguilar, Maria Dolores,
Moreno, Alfonso,
Portolés, Antonio
Objectives: To explore the association between use of antipsychotics and risk of cerebrovascular accident (CVA) in individuals with dementia aged 65 and older.; Design: Population-based case-control study.; Setting: UK-based electronic primary care records in the General Practice Research Database (GPRD).; Participants: Individuals with dementia aged 65 and older registered in the database between January 1, […]
Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial
Lanctôt, Krista L.,
Chau, Sarah A.,
Herrmann, Nathan,
Drye, Lea T.,
Rosenberg, Paul B.,
Scherer, Roberta W.,
Black, Sandra E.,
Vaidya, Vijay,
Bachman, David L.,
Mintzer, Jacobo E.
Background: Little is known about the effect of methylphenidate (MPH) on attention in Alzheimer’s disease (AD). MPH has shown to improve apathy in AD, and both apathy and attention have been related to dopaminergic function. The goal was to investigate MPH effects on attention in AD and assess the relationship between attention and apathy responses.; […]
A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia
Jay Cheol Kwon,,
Eung Gyu Kim,,
Jae Woo Kim,,
Oh Dae Kwon,,
Bong Goo Yoo,,
Hyon Ah Yi,,
Nack Cheon Choi,,
Seon Young Ahn,,
Byung Hwa Lee,,
Myong Jin Kang,,
Dae Seob Choi,
Objectives: To evaluate the efficacy and tolerability of donepezil in patients with Binswanger type subcortical vascular dementia.; Methods: Patients (n = 34, mean age = 71.8 + 7.12) with Binswanger type subcortical vascular dementia from 8 multicenter, according to clinical and neuroradiological working criteria, were selected to receive donepezil 5 mg/day (n = 2) or […]
Phase II crossover trial of varenicline in mild-to-moderate Alzheimer’s disease
Kim, Seong Yoon,
Choi, Seong Hye,
Rollema, Hans,
Schwam, Elias M.,
McRae, Tom,
Dubrava, Sarah,
Jacobsen, Janice
Background: Evidence supports a role of α4β2 receptors in Alzheimer’s disease (AD).; Methods: This Korean, multicenter, double-blind, two-period (6 weeks each), crossover study randomized participants to the order in which they received varenicline (1 mg twice daily) and placebo. Assessments included AD Assessment Scale-Cognitive Subscale (ADAS-Cog) 75, Neuropsychiatric Inventory (NPI), adverse events (AEs) and Columbia-Suicide […]
Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial
Kersten, H.,
Molden, E.,
Tolo, I. K.,
Skovlund, E.,
Engedal, K.,
Wyller, T. B.
Background: Observational studies report a relationship between anticholinergic drug scale (ADS) score and cognitive function. This study investigated whether a reduced ADS score improved cognitive function in a frail elderly population.; Methods: This randomized, controlled, single-blinded trial, recruited long-term residents with an ADS score of greater than or equal to 3 from 22 nursing homes […]
Demonstration of safety in Alzheimer’s patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study
Kennelly, S. P.,
Abdullah, L.,
Paris, D.,
Parish, J.,
Mathura, V.,
Mullan, M.,
Crawford, F.,
Lawlor, B. A.,
Kenny, R. A.
Background: Nilvadipine may lower rates of conversion from mild-cognitive impairment to Alzheimer’s disease (AD), in hypertensive patients. However, it remains to be determined whether treatment with nilvadipine is safe in AD patients, given the higher incidence of orthostatic hypotension (OH) in this population, who may be more likely to suffer from symptoms associated with the […]
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
Kano, Osamu,
Ito, Hirono,
Takazawa, Takanori,
Kawase, Yuji,
Murata, Kiyoko,
Iwamoto, Konosuke,
Nagaoka, Tetsuro,
Hirayama, Takehisa,
Miura, Ken,
Nagata, Riya,
Kiyozuka, Tetsuhito,
Aoyagi, Jo,
Sato, Ryuta,
Eguchi, Teruo,
Ikeda, Ken,
Iwasaki, Yasuo
Clinical trials have shown the benefits of acetylcholinesterase inhibitors, such as donepezil and galantamine, and an N-methyl-d-aspartate receptor antagonist, memantine, in patients with Alzheimer’s disease (AD). However, little is known regarding the effects of switching from donepezil 5 mg/day to galantamine 16 or 24 mg/day, or regarding the effects of adding memantine to established therapy […]